NEWS RELEASE

Revvity Unlocking Possibilities in Cancer Research at AACR

4/4/2024

- Launch of Cellometer™ Ascend™ automated cell counter: With its innovative design, the Cellometer Ascend system has elevated accuracy and reliability in cell counting, accelerating workflows for cancer research and therapeutic development.

- Spotlighting a selection of cancer research technologies: A diverse portfolio of solutions that empowers researchers to explore genetic and mechanistic processes within tumor biology, identify biomarkers, and address challenges in therapeutic development.

- Presenting Revvity: While attending AACR the first time as Revvity, the Company will present its continued commitment to expanding the boundaries of human potential through science.

WALTHAM, Mass. – April 4, 2024 – **Revvity, Inc.** will exhibit at AACR 2024 (booth #731) in its first year as a new brand in San Diego from April 5-10. Revvity's trusted cancer research and discovery portfolio, combined with its latest product launches, helps provide a deeper understanding of tumors and their microenvironment, equipping researchers with the tools to tackle drug resistance barriers and develop more personalized combination cancer therapies.

Empowering researchers to unlock possibilities in cancer research

The pace of innovation in cancer research has been extraordinary, with novel targeted treatments and immunotherapies showing real promise. Today, Revvity's family of innovative products assists researchers in their investigations of cancer providing support for the study of various aspects of the disease, from genomics to

precision medicine and beyond.

“Cancer touches so many of us – it’s one of the leading causes of death worldwide, having a significant impact on communities everywhere. It’s imperative that we work towards reducing its devastating toll through dedicated research efforts,” said Dr. Alan Fletcher, senior vice president life sciences at Revvity. “Conducting research that unlocks the molecular mechanisms driving cancer evolution may be key to discovering personalized combinational therapies and potentially improving patient outcomes. Through our portfolio of trusted solutions, Revvity is poised to be integral in this crusade.”

Solution Highlights at AACR 2024

- Platforms for therapeutic development: Revvity offers cutting-edge solutions for efficient progress in therapeutic development, most notably the new **Cellometer Ascend automated cell counter**, a fast, reliable easy-to-use cell counter and the new Pin-point™ base editing platform for cell and gene therapy research. Revvity’s Certimmune™ Immunology services offer customized immunology services to companies in vaccine and immunotherapy markets for their clinical trials.
- In vivo imaging: With IVIS® Spectrum 2™ platform and Vega™ preclinical ultrasound system, researchers can monitor tumor growth and progression, angiogenesis, and metastases. These technologies also facilitate drug efficacy and toxicology studies and enhance understanding of cancer biology pathways.
- Immuno-oncology research: With robust and high-quality reagents for flow cytometry, cell isolation, immunoassays, multiomics, spatial biology, and cell bioprocessing, BioLegend® is supporting immunology and immuno-oncology workflows to accelerate research breakthroughs.
- Immunoassays: The newest assay kits available in AlphaLISA™ SureFire™ Ultra™, AlphaLISA™, and HTRF™ technologies provide researchers with the tools needed in the race to discovery. The EnVision® Nexus™ and VICTOR Nivo® plate readers also offer powerful and reliable performance.
- Gene modulation: The broadest range of functional genomic tools including Dharmcon™ advanced gene modulation and gene editing solutions.
- Cellular imaging: Advanced cellular imaging systems, including the Opera Phenix® Plus™, which can help researchers better understand biological processes in cancer cells and investigate how tumors interact within their microenvironment.
- Single-cell multiomics: Enhancing key steps of the single-cell sequencing journey, TotalSeq™ multiomics reagents, Multiomics Analysis Software, and Cellaca™ cell counters integrate into existing workflows, paving the way for transformative discoveries.
- Next-generation sequencing workflow: Innovative, end-to-end NGS workflows and applications for ctDNA and cfRNA biomarker identification and characterization. Solutions such as the Omni™ Bead Ruptor® solution for tissue homogenization, chemagic ® 360 nucleic acid isolation, LabChip® GX Touch™ nucleic acid analyzer for

genomic analysis, Fontus® liquid handling workstation, BioQule™ NGS solution, and Mimix™ reference standards, address the full breadth of NGS requirements.

For more information about Revvity and the innovative solutions being showcased at AACR, as well as various presentations and scientific posters that feature Revvity and its products, visit booth #731 and the **AACR2024 events page.**

About Revvity

At Revvity, “impossible” is inspiration, and “can’t be done” is a call to action. Revvity provides health science solutions, technologies, expertise, and services that deliver complete workflows from discovery to development, and diagnosis to cure. Revvity is revolutionizing what’s possible in healthcare, with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics and more.

With 2023 revenue of more than $2.7 billion and over 11,000 employees, Revvity serves customers across pharmaceutical and biotech, diagnostic labs, academia and governments. It is part of the S&P 500 index and has customers in more than 190 countries.

Stay updated by following our **Newsroom**, **LinkedIn**, **X**, **YouTube**, **Facebook** and **Instagram**.